A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma

The GM.CD40L vaccine, which recruits and activates dendritic cells, migrates to lymph nodes, activating T cells and leading to systemic tumor cell killing. When combined with the CCL21 chemokine, which recruits T cells and enhances T-cell responses, additive effects have been demonstrated in non-sma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gray, Jhanelle E., Chiappori, Alberto, Williams, Charlie C., Tanvetyanon, Tawee, Haura, Eric B., Creelan, Ben C., Kim, Jongphil, Boyle, Theresa A., Pinder-Schenck, Mary, Khalil, Farah, Altiok, Soner, Devane, Rebecca, Noyes, David, Mediavilla-Varela, Melanie, Smilee, Renee, Hopewell, Emily L., Kelley, Linda, Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244998/
https://www.ncbi.nlm.nih.gov/pubmed/30209589
http://dx.doi.org/10.1007/s00262-018-2236-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244998/
https://www.ncbi.nlm.nih.gov/pubmed/30209589
http://dx.doi.org/10.1007/s00262-018-2236-7

Ejemplares similares